Recipharm begins construction of vaccine facility in Morocco

28-Jan-2022

This is a major investment in the site by the Moroccan Government, a consortium of the country’s leading banks and Recipharm across the next five years

Global CDMO Recipharm, in charge of building the SENSYO Pharmatech in Morocco, has attended a ceremony to recognise the launch of construction works at its fill finish factory. The ceremony was chaired by His Majesty the King of Morocco, Mohammed VI, in the province of Benslimane.

This is a major investment in the site by the Moroccan Government, a consortium of the country’s leading banks and Recipharm across the next five years to establish capacity and capability for Recipharm to manufacture vaccines and biotherapeutics in the nation. The investment is a step towards managing the pandemic and is hoped to contribute to ensuring vaccine self-sufficiency for the nation and supply to the African continent as a whole.

The facility will integrate pharmaceutical research, clinical development, manufacturing and marketing of pharmaceutical products. It’s hoped to meet national ambitions to make Morocco a biotechnology hub in the region.

SENSYO Pharmatech is aimed to be the largest fill and finish platform in Africa. Initially, it will focus on the manufacture and syringing of vaccines and will feature three industrial lines, forecast to produce more than 100 million units in 2024. These lines will be dedicated to producing vials and vaccines in syringes.

Marc Funk, CEO of Recipharm, said: “We are proud to be involved as the CDMO of choice in this fantastic step forward for Morocco and Africa. Breaking ground on a facility of this magnitude is a significant milestone and reflects the depth of our joint commitment to meeting Morocco’s long term healthcare needs.

Sign up for your free email newsletter

“The past two years have shown the importance of reliable vaccine supply, and we are honoured to have been asked to use our expertise and experience in fill finish manufacturing to produce vaccines and other biotherapeutics in Morocco. Together with all parties involved, we will work to ensure that countries across Africa have greater access to the healthcare they need.”

Companies